Privium Fund Management B.V. Purchases Shares of 48,834 Wave Life Sciences Ltd. (NASDAQ:WVE)

Privium Fund Management B.V. bought a new position in Wave Life Sciences Ltd. (NASDAQ:WVE - Free Report) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 48,834 shares of the company's stock, valued at approximately $400,000.

Several other large investors have also made changes to their positions in WVE. Emerald Advisers LLC purchased a new stake in Wave Life Sciences during the second quarter worth approximately $12,441,000. Emerald Mutual Fund Advisers Trust purchased a new stake in Wave Life Sciences during the 2nd quarter worth $9,086,000. Artal Group S.A. increased its holdings in Wave Life Sciences by 34.7% in the 1st quarter. Artal Group S.A. now owns 4,051,400 shares of the company's stock valued at $24,997,000 after purchasing an additional 1,044,000 shares in the last quarter. Ikarian Capital LLC purchased a new position in Wave Life Sciences in the first quarter valued at about $3,641,000. Finally, Vanguard Group Inc. raised its holdings in shares of Wave Life Sciences by 39.7% during the 1st quarter. Vanguard Group Inc. now owns 1,834,090 shares of the company's stock valued at $11,316,000 after buying an additional 521,665 shares during the period. 89.73% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, CEO Paul Bolno sold 48,366 shares of Wave Life Sciences stock in a transaction dated Wednesday, August 21st. The shares were sold at an average price of $5.78, for a total value of $279,555.48. Following the sale, the chief executive officer now directly owns 359,059 shares in the company, valued at $2,075,361.02. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, CEO Paul Bolno sold 48,366 shares of the firm's stock in a transaction that occurred on Wednesday, August 21st. The stock was sold at an average price of $5.78, for a total value of $279,555.48. Following the sale, the chief executive officer now directly owns 359,059 shares in the company, valued at $2,075,361.02. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Kyle Moran sold 17,146 shares of the company's stock in a transaction dated Wednesday, September 25th. The stock was sold at an average price of $9.00, for a total transaction of $154,314.00. Following the completion of the sale, the chief financial officer now directly owns 19,777 shares of the company's stock, valued at $177,993. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 364,822 shares of company stock valued at $4,645,768 over the last three months. Company insiders own 29.10% of the company's stock.

Analysts Set New Price Targets

WVE has been the topic of a number of recent analyst reports. HC Wainwright reiterated a "buy" rating and issued a $22.00 price objective on shares of Wave Life Sciences in a report on Thursday, October 31st. Raymond James upgraded Wave Life Sciences from an "outperform" rating to a "strong-buy" rating and lifted their price objective for the stock from $13.00 to $22.00 in a report on Wednesday, October 16th. Leerink Partners increased their target price on Wave Life Sciences from $20.00 to $22.00 and gave the company an "outperform" rating in a research note on Wednesday, October 16th. Wells Fargo & Company raised their price target on shares of Wave Life Sciences from $11.00 to $22.00 and gave the stock an "overweight" rating in a research report on Wednesday, October 16th. Finally, B. Riley upped their price target on shares of Wave Life Sciences from $19.00 to $22.00 and gave the company a "buy" rating in a report on Monday, November 4th. Two research analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Wave Life Sciences currently has an average rating of "Moderate Buy" and an average target price of $19.78.

Wave Life Sciences Stock Performance

Shares of NASDAQ WVE traded up $1.61 during midday trading on Friday, hitting $16.44. The company's stock had a trading volume of 2,395,131 shares, compared to its average volume of 2,218,789. The firm has a market cap of $2.05 billion, a P/E ratio of -28.84 and a beta of -1.20. Wave Life Sciences Ltd. has a 1-year low of $3.50 and a 1-year high of $16.47. The firm's fifty day moving average price is $9.77 and its 200-day moving average price is $7.19.

Wave Life Sciences (NASDAQ:WVE - Get Free Report) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.25) earnings per share for the quarter, missing analysts' consensus estimates of ($0.16) by ($0.09). Wave Life Sciences had a negative return on equity of 1,395.99% and a negative net margin of 66.50%. The company had revenue of $19.69 million for the quarter, compared to analyst estimates of $24.80 million. During the same quarter in the previous year, the company posted ($0.20) earnings per share. As a group, research analysts predict that Wave Life Sciences Ltd. will post -1.01 earnings per share for the current fiscal year.

Wave Life Sciences Profile

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.